Cure of malignant and non-malignant hematological diseases is potentially possible after allogeneic hematopoietic stem cell transplantation (HCT). Accurate evaluation of the risk–benefit ratio for an ...
This article is written by Ann O’Neill, director of clinical operations at Regent Surgical Health. This article was originally printed in the Regent Surgical Health newsletter and has been republished ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback